Wang, Y., Zhou, J. (2026). A prospective, single-arm phase II study of trilaciclib combined with immunotherapy and chemotherapy as first-line treatment for metastatic/recurrent esophageal squamous cell carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.411